Moleculin's Annamycin Shows Strong Cardiac Safety Profile in R/R AML Patients, Addressing Key Treatment Barrier
MBRX sits 39% above its 52-week low of $1.79 on light trading volume (0.1× avg).
Summary
Moleculin Biotech announced positive cardiac safety data for its lead drug Annamycin, demonstrating no significant cardiotoxicity even at high doses, which could expand its use in relapsed/refractory AML.
Key Events · Product Development and Regulatory · MBRX
-
Positive Cardiac Safety Data
An independent review found no clinically significant cardiotoxicity for Annamycin across 90 patients in five trials, even at cumulative anthracycline-equivalent doses exceeding conventional lifetime limits.
-
Addresses Anthracycline Limitation
The data shows Annamycin maintains a stable mean ejection fraction and avoids cardiac issues common with conventional anthracyclines, addressing a principal barrier to their use.
-
Potential for Broader Use
This favorable cardiac safety profile could enable continued anthracycline-based treatment for heavily pretreated relapsed/refractory AML patients and potentially expand Annamycin's use in other oncology indications.
Analysis · MBRX · Life Sciences
This is a significant positive development for Moleculin Biotech, especially given its recent "going concern" warning and dilutive financing. Annamycin's cardiac safety profile addresses a critical limitation of traditional anthracyclines, which are effective but cardiotoxic. Demonstrating safety at high cumulative doses de-risks a major concern for the drug and could significantly broaden its market potential in relapsed/refractory AML and other cancers. This news provides a much-needed positive clinical update that could improve investor confidence and potentially aid future capital-raising efforts.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 36.8% of the 990 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.55%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MBRX was trading at $2.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.2M. The 52-week trading range was $1.79 to $28.61. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.